#3563
Can tumor absorbed dose predict response to Peptide Receptor Radionuclide Therapy (PRRT) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs)?
Introduction:
Tumor dosimetry protocols following Peptide Receptor Radionuclide Therapy (PRRT) have not yet been standardised and tumor absorbed dose does not hold clear value in predicting response to treatment.
Conference:
Presenting Author:
Mileva M
Authors:
Mileva M,
Marin G,
Levillain H,
van Bogaert C,
Critchi G,
Keywords:
PRRT,
tumor dose,
68Ga-DOTATATE,
SUVmax,
response,
#3270
Exploration of Ga-68 DOTA PET radiomics to predict the absorbed dose of Lu-177 DOTATATE® therapy of midgut neuroendocrine tumors
Introduction:
Lu-177 DOTATATE® is a proficient systemic irradiation with heterogeneous individual consequences due to tumor burden, uptake and elimination. Current dosimetry protocols seem not accurate enough to predict efficacy or toxicity.
Conference:
18th Annual ENETS Concerence (2021)
Presenting Author:
Courbon F
Authors:
Brahmi S,
Vallot D,
Vija L,
Dierickx L,
Courbon F,
Keywords:
midgut NET,
Ga DOTA PET CT,
LuPRRT,
PET metrics,
SUV,
tumor absorbed dose,